Attila von Hankó

Transfer of responsibilities and strategic support to new management team of vaxxinova International.

As trusted member in family owned holding company overall responsibility for establishment, strategic planning and operational development of vaxxinova, an independent group of international companies with focus on research & development, manufacturing, sales & marketing of veterinary vaccines. As Managing Director direct operational responsibility for organisational and business development of vaxxinova GmbH in Germany. Co-management and development of vaxxinova Japan as Chairman. Extension of group activities through dedicated development of fish (aquaculture) vaccines at vaxxinova Norway. In Dec 2014 successful acquisition of Italy based IZO S.r.l..

Internal and external repositioning of the strategically important subsidiary (only foreign activity with own R&D activities) with high priority on change management and improving compatibility of local structures/culture with global requirements. Consequent focus on key account management and competent technical support. Successful development of leading market positions in targeted key segments of veterinary vaccines for livestock and companion animals. Strong turnover growth with sustainable improvement of profitability, Pioneer success in development and marketing of innovative vaccines for fish (aquaculture).

Strengthening and repositioning of local business activities based on insourcing of critical business functions formerly performed by external partners (import, warehousing, logistics, sales & marketing, TechService). Through dedicated, customer focused TechService and introduction of innovative products and concepts significant increase of market shares and profitability with vaccines and pharmaceuticals for livestock- and companion animals.

Establishment (partially) and continued improvement of country organisations and business activities in seven countries, with main focus on Taiwan, Indonesia, Philippines, Korea, Vietnam). Development of strategic alliances with selected key accounts.

Initial key focus on development of competent, motivated and loyal local teams at Representative Offices in HoChiMinh and Hanoi, followed by successful turnaround of previously loss making country activities through substantial turnover increase combined with reduction of costs. Continuous improvement of trust and support from Hoechst AG Business Units, including assignment for investigation of potential for direct investments in Vietnam.

Establishment and management of internal consulting unit (PCU) to support Hoechst AG Business Units in evaluation and execution of opportunities for direct investments in China. Major role of PCU in search and selection of local partners as well as negotiation and conclusion of joint ventures. Successful engagement of PCU in 15 projects covering chemicals, agriculture, and human pharmaceuticals. Personal engagement as Team leader for US$ 100 mio project in Shanghai (SGL Carbon). Direct responsibility for government relations, including organisation of 10 day visit of Hoechst AG board members, involving personal meetings with China President Jiang Zemin, Vice Premier Li Lanqing, Major of Shanghai und three Ministers.

Coordination of price strategies für key products of Business Unit Chemicals and support to management on feasibility study for divestment of German daughter company. Parallel „On-the-job-off-the-job“ studies for company sponsored MBA at „Universitätsseminar der Wirtschaft / Schloss Gracht“ (today ESMT / Berlin).

Development of motivated team of senior and junior sales managers. Significant expansion of sales activities to seven Hoechst AG Business Units and five daugther companies and products covering basic chemicals, speciality chemicals, engineering plastics and pharma raw materials. Strong growth of turnover and contribution margin through realization of new business potentials in Taiwan.